Drug Type Small molecule drug |
Synonyms (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid, Cefotetan disodium (USP), Cefotetan sodium (JAN) + [6] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Dec 1985), |
Regulation- |
Molecular FormulaC17H17N7NaO8S4 |
InChIKeyBTOFDTWBLNLGSY-DWUNWFSHSA-N |
CAS Registry74356-00-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02228 | Cefotetan Disodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | US | 27 Dec 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacterial Infections | Phase 2 | CN | 21 Feb 2017 | |
Genitourinary tract infection | Phase 2 | CN | 12 Apr 2012 | |
Respiratory Tract Infections | Phase 2 | CN | 12 Apr 2012 |
Phase 3 | - | 1,002 | gaopxhgxee(vxyrcivlox) = the overall incidence of Clostridium difficile infection was 1.7% in the ertapenem group and 0.6% in the cefotetan group (P=0.22) jsbtlrpccz (hjnehurcja ) | - | 21 Dec 2006 | ||